Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGF

27 Sept 2016

Abstract excerpt

OBJECTIVE: To estimate the patient-specific risk of pre-eclampsia (PE) at 31-34 weeks' gestation by a combination of maternal characteristics and medical history with multiples of the median (MoM) values of serum placental growth factor (PlGF) and serum soluble fms-like tyrosine kinase-1 (sFlt-1) and to compare the performance of screening to that achieved by the sFlt-1/PlGF ratio. METHODS: This was a prospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Maternal and fetal healthcare
Share to Pregnancy and preeclampsia studies
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27671370
DOI: 10.1002/uog.17307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of screening for pre-eclampsia at 31-34 weeks' gestation by sFlt-1/PlGF ratio and a method combining maternal factors with sFlt-1 and PlGFPMID 27671370Read ↗

The prognostic utility of soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF) biomarkers for predicting preeclampsia: a secondary analysis of data from the INSPIRE trialSemantic proximity Read ↗

Diagnostic accuracy of sFlt1/PlGF ratio as a marker for preeclampsiaSemantic proximity Read ↗

Prognostic value of angiogenic markers in pregnancy with fetal growth restrictionSemantic proximity Read ↗

First-trimester screening with specific algorithms for early- and late-onset fetal growth restrictionSemantic proximity Read ↗

Biomarkers and the Prediction of Adverse Outcomes in PreeclampsiaSemantic proximity Read ↗

Placental growth factor and fetoplacental Doppler indices in combination predict preterm birth reliably in pregnancies complicated by fetal growth restrictionSemantic proximity Read ↗

sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss PerspectiveSemantic proximity Read ↗

Screening for pre‐eclampsia with competing‐risks model using placental growth factor measurement in blood samples collected before 11 weeks' gestationSemantic proximity Read ↗

The ratio of soluble fms-like tyrosine kinase 1 to placental growth factor predicts time to delivery and mode of birth in patients with suspected preeclampsia: a secondary analysis of the INSPIRE trialSemantic proximity Read ↗

Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian populationSemantic proximity Read ↗

A New Model for Screening for Late-Onset Preeclampsia in the Third TrimesterSemantic proximity Read ↗

sFlt ‐1/ PlGF ratio and timing of delivery in early‐onset fetal growth restriction with antegrade umbilical artery flowSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.